Faeth Therapeutics Shares Outstanding History (FTH)
Faeth Therapeutics reported 1.3M shares outstanding at the end of fiscal 2025.
View full Faeth Therapeutics company overviewFaeth Therapeutics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 1.3M | 2,745 | +0.22% |
| 2024 | 2024-12-31 | 1.3M | 7,430.6 | +0.59% |
| 2023 | 2023-12-31 | 1.3M | −286,698.6 | −18.64% |
| 2022 | 2022-12-31 | 1.5M | 7,756.55 | +0.51% |
| 2021 | 2021-12-31 | 1.5M | 1.4M | +1532.11% |
| 2020 | 2020-12-31 | 93,771.1 | — | — |
Faeth Therapeutics quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 25.8M | 24.6M | +1948.14% |
| Q1 2026 | 2026-03-31 | 1.3M | 79,929.6 | +6.34% |
| Q4 2025 | 2025-12-31 | 1.3M | 2,655.85 | +0.21% |
| Q3 2025 | 2025-09-30 | 1.3M | 3,721.05 | +0.30% |
| Q2 2025 | 2025-06-30 | 1.3M | 5,073.35 | +0.40% |
| Q1 2025 | 2025-03-31 | 1.3M | 6,705.5 | +0.53% |
| Q4 2024 | 2024-12-31 | 1.3M | 7,519.75 | +0.60% |
| Q3 2024 | 2024-09-30 | 1.3M | 7,743.1 | +0.62% |
| Q2 2024 | 2024-06-30 | 1.3M | −72,974.3 | −5.49% |
| Q1 2024 | 2024-03-31 | 1.3M | −294,869.15 | −19.04% |
| Q4 2023 | 2023-12-31 | 1.3M | −286,698.6 | −18.64% |
| Q3 2023 | 2023-09-30 | 1.2M | −286,220.2 | −18.63% |
| Q2 2023 | 2023-06-30 | 1.3M | −206,855.1 | −13.47% |
| Q1 2023 | 2023-03-31 | 1.5M | 14,426.4 | +0.94% |
| Q4 2022 | 2022-12-31 | 1.5M | 7,756.55 | +0.51% |
| Q3 2022 | 2022-09-30 | 1.5M | 6,621.3 | +0.43% |
| Q2 2022 | 2022-06-30 | 1.5M | 6,621.3 | +0.43% |
| Q1 2022 | 2022-03-31 | 1.5M | 4,715.9 | +0.31% |
| Q4 2021 | 2021-12-31 | 1.5M | 1.4M | +1532.11% |
| Q3 2021 | 2021-09-30 | 1.5M | — | — |
| Q2 2021 | 2021-06-30 | 1.5M | — | — |
| Q1 2021 | 2021-03-31 | 1.5M | — | — |
| Q4 2020 | 2020-12-31 | 93,771.1 | — | — |
Faeth Therapeutics shares outstanding trends
Over the last five reported fiscal years, Faeth Therapeutics's shares outstanding moved from 93,771.1 to 1.3M, a change of 1.2M. The latest reported quarter, Q2 2026, shows 25.8M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Faeth Therapeutics filings at SEC.gov ↗